Harvard College

Ucbbiopharma Srl

Ucb Biopharma Sprl

Carl Brendan Doyle

Kerry Louise Tyson

Ralph Adams

Karine Jeannine Madeleine Hervé

Gökhan S Hotamisligil

Feyza Engin

Elisabeth Helen Roberts

Scott B Widenmaier

Adrian Richard Moore

Shauna Mhairi Wales

Mehmet F Burak

Daniel John Lightwood

Mark Ellis

Lara Kevorkian

Diane Marshall

Andrew Charles Payne

Joanne Elizabeth Compson

Alison Turner

Kate Louise Dixon

Maria Margarida Gouveia Sancho

Raymond Anthony Jupp

Joseph Michael David Rastrick

Monika-Sarah Schulze

Karen Inouye

Helene Bon

This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as 'aP2') for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders

The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.

Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis

Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders

Growing community of inventors

Slough, United Kingdom

Carl Brendan Doyle